Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that John Celebi, president and chief executive officer, will participate in a panel titled ‘Novel Approaches in Immunotherapy’ at Cantor Fitzgerald’s Future of Oncology Virtual Symposium on Monday, April 3rd at 10.00 a.m. ET.

About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

Staff

Recent Posts

Unicon Pharma Announces Strategic Partnership with VRR Life Sciences to Expand Global CSV Capabilities and Support Digital Transformation in Life Sciences

SOUTH PLAINFIELD, N.J., May 21, 2025 /PRNewswire/ -- Unicon Pharma, a leading provider of compliance,…

3 hours ago

Introducing Mapping Suite from Dickson

Automation Meets Audit-Readiness with New Cloud-Based Solution for Streamlined Temperature Mapping ADDISON, Ill., May 21,…

3 hours ago

Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio

Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in…

3 hours ago

Lethal mutations in pregnancy loss

REYKJAVIK, Iceland, May 21, 2025 /PRNewswire/ -- In a study published in Nature today "Sequence…

3 hours ago

Milligram Health Launches Phios: An Optimization Infrastructure for Community Pharmacies

CINCINNATI, May 21, 2025 /PRNewswire/ -- Milligram Health (MgH), a pharmacy strategy and analytics firm…

3 hours ago